Drug Trial Radar · NCT06273553
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
Last checked: Nov 19, 2026Latest source record: Feb 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
39
Planned (sponsor's estimate)
Start
Mar 2024
Primary completion
Oct 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- RinuaGene Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).
Conditions
- Human Papillomavirus Associated Intraepithelial Neoplasia
- Cervical Intraepithelial Neoplasia Grade 2/3
- Human Papillomavirus Type 16 Infection
- Human Papillomavirus Type 18 Infection
Interventions
RG002 injectionBiological
In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability of RG002 Injection, measured by the incidence of adverse eventsTime frame: Week 9
- Part A: Maximum tolerated dose (MTD) and/or RP2D of RG002 InjectionTime frame: MTD:Week 9; RP2D: Week 36
- Part B: Primary efficacy of RG002 Injection, measured by the proportion of subjects with histopathological regressionTime frame: Week36
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.